Flashpoint Therapeutics
PrivateLast Round
Seed
Oct 25, 2023
Est. Valuation
$35M
Total Funding Raised
$10M
Company Overview
Flashpoint Therapeutics operates in Healthcare & Life Sciences and is based in Evanston, Illinois. Its latest recorded funding round was a Seed round in October 2023.
Flashpoint Therapeutics is a biotechnology company that develops precision-engineered structural nanomedicines for cancer and other diseases by co-delivering RNA, DNA, and peptide cargo to specific cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Flashpoint Therapeutics Comparables
Compare Flashpoint Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SNC Therapeutics, Inc. | 87% | |
| DNA Nanobots | 85% | |
| Entos Pharmaceuticals | 83% |
For institutional investors. Book with your work email.
Flashpoint Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 25, 2023 | ||||
| Pre Seed | Jan 30, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Flashpoint Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Beta Lab | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2025
Barry Labinger appointed as new Chief Executive Officer.
- Oct 25, 2023
$10M raised, led by Beta Lab.
For institutional investors. Book with your work email.
Flashpoint Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Flashpoint Therapeutics's valuation, stock price, and market status.
Is Flashpoint Therapeutics a public or private company?
Flashpoint Therapeutics is a private company.
What is the current stock price of Flashpoint Therapeutics?
Flashpoint Therapeutics is a private company, so its shares have no public market price. Caplight tracks Flashpoint Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Flashpoint Therapeutics worth (valuation)?
Flashpoint Therapeutics's valuation is estimated at $35.0M based on funding round data.
Can I buy Flashpoint Therapeutics stock?
Flashpoint Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Flashpoint Therapeutics's last funding round?
Flashpoint Therapeutics's most recent funding round was Seed on October 25, 2023.
Who are the main investors in Flashpoint Therapeutics?
Key investors in Flashpoint Therapeutics include Beta Lab.
Will Flashpoint Therapeutics IPO soon?
No public IPO plans have been announced for Flashpoint Therapeutics.
How can I track Flashpoint Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Flashpoint Therapeutics's shares on secondary markets.